92 Results for "

c-Kit kinase

" in MedChemExpress (MCE) Product Catalog:
Products (92)

92 Results for "c-Kit kinase" in MCE Product Catalog:

  • Targets Recommended:
161
161 Publications Verification
Cat. No.: HY-16749
CAS No.: 1029044-16-3
Synonyms: PLX-3397
Target:  

c-Fms c-Kit Apoptosis

Research Areas:  

Cancer

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib (PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib (PLX-3397) induces cell apoptosis and has anti-tumor activity. Pexidartinib has limited permeability to the blood-brain barrier, primarily through ABCB1 .
loading...
    loading...
161
161 Publications Verification
Cat. No.: HY-16749A
CAS No.: 2040295-03-0
Synonyms: PLX-3397 hydrochloride
Target:  

c-Fms c-Kit Apoptosis

Research Areas:  

Cancer

Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity .
loading...
    loading...
127
127 Cited Publications
Cat. No.: HY-15463
CAS No.: 152459-95-5
Purity:  99.95%
Synonyms: STI571; CGP-57148B
Research Areas:  

Cancer

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
127
127 Cited Publications
Cat. No.: HY-50946
CAS No.: 220127-57-1
Synonyms: STI571 Mesylate; CGP-57148B Mesylate
Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
loading...
    loading...
39
39 Cited Publications
Cat. No.: HY-10230
CAS No.: 120685-11-2
Purity:  99.91%
Synonyms: PKC412; CGP 41251
Research Areas:  

Cancer

Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-10205
CAS No.: 288383-20-0
Purity:  99.87%
Synonyms: AZD2171
Cediranib (AZD2171) is a highly potent, orally available and blood-brain barrier permeability VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-50905
CAS No.: 405169-16-6
Synonyms: CHIR-258; TKI258
Target:  

FLT3 c-Kit FGFR VEGFR PDGFR c-Fms

Research Areas:  

Cancer

Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-10207
CAS No.: 692737-80-7
Purity:  99.75%
Synonyms: CHIR-258 lactate; TKI-258 lactate
Target:  

FLT3 c-Kit FGFR VEGFR PDGFR

Research Areas:  

Cancer

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10206
CAS No.: 850879-09-3
Purity:  99.40%
Synonyms: MP470; HPK 56
Research Areas:  

Cancer

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair . Antineoplastic activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10408
CAS No.: 623142-96-1
Purity:  99.51%
Target:  

c-Fms VEGFR c-Kit PDGFR

Research Areas:  

Inflammation/Immunology

Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0419
CAS No.: 491-50-9
Synonyms: Quercetin-7-O-β-D-glucopyranoside
Quercimeritrin (Quercetin-7-O-β-D-glucopyranoside) is an orally active α-glucosidase inhibitor (with an IC50 of 79.88 μM against the Saccharomyces cerevisiae enzyme) and a P-gp substrate, with anti-angiogenic and antioxidant activities. Quercimeritrin does not cross the blood-brain barrier and does not inhibit cytochrome P450 enzymes. Quercimeritrin precisely binds to and inhibits the active sites of c-Kit, MMP-2, Aurora-A kinases and α-glucosidase, thereby disrupting target functions. Quercimeritrin effectively regulates postprandial blood glucose and also exhibits significant anti-angiogenic activity, which inhibits endothelial cell proliferation and microvascular growth. Quercimeritrin can be used in the research of diabetes and breast cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P80619
Synonyms: Kit; SCFR; Mast/stem cell growth factor receptor Kit; SCFR; Piebald trait protein; PBT; Proto-oncogene c-Kit; Tyrosine-protein kinase Kit; p145 c-Kit; v-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; CD antigen CD117

Host:  

Rabbit

Application:  

WB, IHC-P

Reactivity:  

Human

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18302
CAS No.: 1003311-62-3
Target:  

c-Kit

Research Areas:  

Inflammation/Immunology

c-Kit-IN-5 is potent inhibitor of c-Kit, with IC50s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15463S
CAS No.: 1092942-82-9
Purity:  99.85%
Synonyms: STI571-d8; CGP-57148B-d8
Imatinib-d8 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .
loading...
    loading...
Cat. No.: HY-108713
CAS No.: 1044040-56-3
Purity:  98.13%
Synonyms: SHR1020
Target:  

VEGFR PDGFR Apoptosis

Research Areas:  

Cancer

Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively . Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis .
loading...
    loading...
Cat. No.: HY-156619
CAS No.: 1426449-01-5
Purity:  99.32%
Synonyms: EVT-8565072; THB335
Target:  

c-Kit PDGFR

Labuxtinib (EVT-8565072; THB335) is a potent dual inhibitor of c-Kit and PDGFR. Labuxtinib exhibits potent inhibitory activity against wild-type c-Kit (IC50 = 0.005 μM). Labuxtinib inhibits SCF-dependent and PDGF-dependent cell proliferation, and blocks the proliferation of cells dependent on c-Kit or PDGFR signaling pathways. In animal models of skin allergy, Labuxtinib depletes skin mast cells and significantly alleviates anaphylactic shock responses. Labuxtinib can be used in research on mast cell-related diseases, respiratory diseases, inflammatory diseases, fibrotic diseases, metabolic diseases, and other related conditions .
loading...
    loading...
Cat. No.: HY-124526
CAS No.: 1256349-48-0
Purity:  99.28%
Synonyms: Ibcasertib; CS2164
Research Areas:  

Cancer

Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects .
loading...
    loading...
Cat. No.: HY-103032
CAS No.: 778274-97-8
Purity:  99.34%
Target:  

PDGFR c-Kit Bcr-Abl

Research Areas:  

Cancer

Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .
loading...
    loading...
Cat. No.: HY-15463S1
CAS No.: 1134803-16-9
Purity:  99.97%
Synonyms: STI571 d4; CGP-57148B d4
Imatinib-d4 (STI571-d4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .
loading...
    loading...
Cat. No.: HY-13342AS
CAS No.: 2468771-43-7
Purity:  92.56%
Synonyms: YN968D1-d8 free base
Apatinib-d8 (free base) is the deuterium labeled Apatinib free base . Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ .
loading...
    loading...